Key takeaways of the Human Recombinant Insulin Market:
The global human recombinant insulin market is expected to expand at a CAGR of 7.2% during the forecast period (2018 – 2026), owing to increasing technological advancement in recombinant human insulin by various key players.
Long acting human insulin are projected to grow with higher pace during the forecasted period in the product type segment, owing to their higher efficiency and ability to offer consistent insulin delivery throughout the day, lasting 24 hours.
Other brands hold major market share in brand segment, due to the involvement of innovative and new human recombinant insulin portfolio with increased patent expiry period such as Toujeo, Tresiba, Basaglar, among others; in this segment, which further expected to capture higher market share, during the forecast period.
Retail pharmacies holds largest market share in distribution channel segment. As retail pharmacies offer direct access to full range of diabetes products, covering all prescription and over-the-counter products for patients with diabetes.
Some of the major players operating in global human recombinant insulin market include Novo Nordisk A/S, Eli Lilly and Company, Sanofi S.A., Julphar Gulf Pharmaceutical Industries, Biocon Limited, Bioton S.A., Gan & Lee Pharmaceuticals, Ltd., Zhuhai United Laboratories Co., Ltd., Wanbang Biopharmaceuticals Co., Ltd. and Dongbao Enterprise Group Co., Ltd.